Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah JO, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li P-Z, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102756]

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Baah JO, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata KE, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion-M-J, Li P-Z, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102755]

Samper E. ¿Y por qué no una farmacéutica pública?. eldiario.es 2018:19 de abril. [Ref.ID 102705]

Anónimo. Acide obéticholique et cholangite biliaire primitive. Prescrire 2018;38:326-7. [Ref.ID 102652]

Anónimo. Flupirtine: Serious liver problems. European Union. WHO Drug Information 2018;32:21. [Ref.ID 102625]

Anónimo. Artemisia annua soft gel capsules: Reports of liver damage. New Zealand. WHO Drug Information 2018;32:20. [Ref.ID 102624]

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]

Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. [Ref.ID 102549]

Anónimo. Esmya® : vigilar la función hepática y no iniciar nuevos tratamientos como medidas cautelares. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:9 de febrero. [Ref.ID 102526]

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

Mole B. “Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Ars Technica 2018:12 de abril. [Ref.ID 102511]

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

Anónimo. EMA committee calls for flupirtine to be taken off the market. DIA Daily 2018:7. [Ref.ID 102454]

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

Anónimo. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio: actualización de la información. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 102152]

Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024. [Ref.ID 102147]

Anónimo. FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. FDA U.S. Food and Drug Administration 2017:21 de septiembre. [Ref.ID 102061]

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

Anónimo. EMA’s PARC recommends modified-release paracetamol be removed from market. DIA Daily 2017:2. [Ref.ID 102044]